Le Lézard
Classified in: Health, Science and technology
Subjects: Personnel, Share Issue

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)


Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee(s) under Xeris' Inducement Equity Plan.

Xeris' Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments, and are subject to the employees' continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris' Inducement Equity Plan and forms of award agreements covering the grants.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing's syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSoltm and XeriJect®, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.


These press releases may also interest you

3 mai 2024
Chemistree Directors Ratify Debenture Restructuring
Chemistree Technology Inc. and (US OTC: CHMJF) (the "Company" or "Chemistree"), announces that its board of directors (the "Board") has approved a restructuring transaction (the "Restructuring Transaction"), pursuant to which all of the principal of...

3 mai 2024
United Imaging to Unveil Industry-Leading MRI Advancements at ISMRM 2024
United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will unveil its latest MRI technology, boasting incredible advancements across various fronts, as a Gold sponsor at this year's ISMRM meeting. The...

3 mai 2024
/C O R R E C T I O N -- Mitsubishi Tanabe Pharma America/
In the news release, Mitsubishi Tanabe Pharma America to Present RADICAVA ORS® (edaravone) Real-World Data at the Professional Society for Health Economics and Outcomes Research 2024 Annual Meeting, issued 03-May-2024 by Mitsubishi Tanabe Pharma...

3 mai 2024
Affiliated Dermatologists Notifies of Data Security Incident
Affiliated Dermatologists (AD) is providing notice of a recent data security incident. At this time, AD is not aware of any misuse of any personal information in connection with this incident. What Happened? On March 5, 2024, AD detected it was the...

3 mai 2024
Statement: The Government of Canada provides an update on the Highly Pathogenic Avian Influenza
With recent news of dairy cattle in the United States testing positive for the Highly Pathogenic Avian Influenza (HPAI) and reports of fragments of HPAI detected in pasteurized milk sold in the U.S., we understand that Canadians may be concerned...

3 mai 2024
Butterfly Medical Welcomes Experienced Urology Executive to its Helm
Butterfly Medical Ltd, an early-stage medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), is excited to announce the hiring of Patrick MacCarthy as CEO. ...

More news about Health...


News published on and distributed by: